Canadian Respiratory Journal / 2018 / Article / Tab 1

Research Article

Prevalence and Prognosis of Portopulmonary Hypertension in 223 Liver Transplant Recipients

Table 1

Demographic and clinical features of all included patients.

VariablePoPHNon-PoPH

Age (years)53.1 ± 8.750.6 ± 8.90.31
Gender (male/female), 7/7163/460.03 (Fisher)
Etiology of liver disease, (%)0.28 (Fisher)
 HBV infection8 (57.1)153 (73.2)
 HCV infection1 (7.1)9 (4.3)
Autoimmune hepatitis2 (14.3)17 (8.1)
Alcoholic0 (0)10 (4.8)
Others3 (21.4)20 (9.6)
With hepatocellular carcinoma, (%)0.152
 Yes4 (28.6)101 (48.3)
 No10 (71.4)108 (51.7)
Cirrhosis, 0.364
 Yes12191
 No218
Ascites, 0.249
 Yes770
 No7139
Portal hypertension, 0.001
 Yes14115
 No094
Child–Pugh score9 (6–11)7 (5–12)0.001
MELD20.5 (8–31)12 (6–40)0.006
CO (L/min)6.9 ± 2.86.1 ± 1.80.27
ALT (IU/L)35.5 (4–290)31.5 (6–652)0.54
AST (IU/L)78 (13–1098)46.9 (15.5–602)0.02
TBIL (mg/dL)6.9 (1.1–37.9)2.1 (0.2–54.6)0.005
Creatinine (mg/dL)0.7 (0.4–1.3)0.7 (0.3–80.4)0.29
ALB (g/L)30.1 ± 4.534.4 ± 60.01
Hb (g/L)85.1 ± 17.9109.8 ± 25.5<0.001

HBV, hepatitis B virus; HCV, hepatitis C virus; MELD, Model for End-Stage Liver Disease; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TBIL, total bilirubin; ALB, albumin; Hb, hemoglobin.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.